Thus, clinical studies of vaccination against HER3 in combination with other therapies, such as trastuzumab to treat the refractory HER2-overexpressing breast cancers or chemotherapy like paclitaxel against triple-negative breast cancers may show a plausible therapeutic efficacy. This evidence concerns the gene ERBB3 and breast carcinoma.